Luo Fang

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 8

Top Topics

Replacement Therapy

Radical Prostatectomy

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Haiying Ding, Shujing Li, Xinglu Xu, Weiben Xu, Chaoneng He, Wen-Xiu Xin, Zha-Jun Zhan, Luo Fang
Cost-effectiveness analysis of rezvilutamide versus bicalutamide in the treatment of metastatic hormone-sensitive prostate cancer. BMJ open 14 (7) (2024)
Haiying Ding, Shujing Li, Xinglu Xu, Weiben Xu, Chaoneng He, Wen-Xiu Xin, Zha-Jun Zhan, Luo Fang
Cost-effectiveness analysis of rezvilutamide versus bicalutamide in the treatment of metastatic hormone-sensitive prostate cancer. BMJ open 14 (7) (2024)
Haiying Ding, Shujing Li, Xinglu Xu, Weiben Xu, Chaoneng He, Wen-Xiu Xin, Zha-Jun Zhan, Luo Fang
Cost-effectiveness analysis of rezvilutamide versus bicalutamide in the treatment of metastatic hormone-sensitive prostate cancer. BMJ open 14 (7) (2024)
Qilu Fang, Wenxiu Xin, Liangsheng Chen, Yuxuan Fu, Yajun Qi, Haiying Ding, Luo Fang
Caffeic acid phenethyl ester suppresses metastasis of breast cancer cells by inactivating FGFR1 via MD2. PloS one 18 (7) (2023)
Haiying Ding, Chaoneng He, Yinghui Tong, Qilu Fang, Xiufang Mi, Lingya Chen, Wenxiu Xin, Luo Fang
Cost-effectiveness of PARP inhibitors in malignancies: A systematic review. PloS one 17 (12) (2022)
Haiying Ding, Chaoneng He, Yinghui Tong, Qilu Fang, Xiufang Mi, Lingya Chen, Wenxiu Xin, Luo Fang
Cost-effectiveness of PARP inhibitors in malignancies: A systematic review. PloS one 17 (12) (2022)
Haiying Ding, Chaoneng He, Yinghui Tong, Qilu Fang, Xiufang Mi, Lingya Chen, Wenxiu Xin, Luo Fang
Cost-effectiveness of PARP inhibitors in malignancies: A systematic review. PloS one 17 (12) (2022)
Haiying Ding, Chaoneng He, Yinghui Tong, Qilu Fang, Xiufang Mi, Lingya Chen, Wenxiu Xin, Luo Fang
Cost-effectiveness of PARP inhibitors in malignancies: A systematic review. PloS one 17 (12) (2022)